1. National Institute for Health and Care Excellence . Cardiovascular disease: risk assessment and reduction including lipid modification (NG238) [online]. 2023. Available: www.nice.org.uk/guidance/ng238 [Accessed 4 Aug 2024].
2. Scottish Medicines Consortium . Icosapent ethyl (Vazkepa) [online]. 2023. Available: https://scottishmedicines.org.uk/medicines-advice/icosapent-ethyl-vazkepa-ft-resub-smc2602/ [Accessed 4 Aug 2024].
3. Joint Formulary Committee . British National Formulary [online]. 2024. Available: https://bnf.nice.org.uk/ [Accessed 4 Aug 2024].
4. National Institute for Health and Care Excellence . Clinical knowledge summaries: CVD risk assessment and management. 2024. Available: https://cks.nice.org.uk/topics/cvd-risk-assessment-management/
5. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk